Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

Obesity Clinical Trial

— OB-HTN  

Official title:

Sympathetic Neural Patterns and Transduction in Obesity-associated Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04838678
• Other study ID #: STU2020-0749
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 18, 2021
• Est. completion date: September 2025

Study information

• Verified date: August 2023
• Source: University of Texas Southwestern Medical Center
• Contact: Christopher M Hearon, Ph.D.
• Phone: 214-345-4624
• Email: christopher.hearon[@]utsouthwestern.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Control - BMI<30, age 18-55
• Hypertensive - BMI<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI>30, age 18-55 Obese-hypertensive- BMI>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Exclusion Criteria: All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,

Related Conditions & MeSH terms

• Hypertension
• Obesity

Intervention

Drug:
• Neuropeptide Y
intra-arterial infusion of neuropeptide Y

Locations

Country	Name	City	State
United States	University of Texas Southwestern Medical Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood flow measured by doppler ultrasound	brachial and femoral artery blood flow	Acutely on the day of study
Primary	Muscle sympathetic nervous system activity	recording of sympathetic nervous system activity from the peroneal or radial nerve	Acutely on the day of study